Intersect ENT Inc. (XENT)

Name: Intersect ENT Inc. (XENT) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Intersect ENT Inc. (XENT)

Stock Card

$28.24

$0.00 (0.00%)

As on 13-May-2022 09:30EDT

Market cap

$955 Mln

Revenue (TTM)

$104 Mln

P/E Ratio

P/B Ratio

56.4

Div. Yield

0 %

Intersect ENT (XENT) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 28.24 High: 28.24

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$-168 Mln
ROE

-1.8 %
ROCE

-- %
Industry P/E

44.46
EV/EBITDA

0
Debt to Equity

-1.5
Book Value

$--
EPS

$-5.1
Face value

--
Shares outstanding

33,813,700

10 Years Aggregate

CFO

$-237.64 Mln

EBITDA

$-393.21 Mln

Net Profit

$-419.19 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Intersect ENT (XENT)	3.4	1.1	3.3	60.3	0.9	4.1	--
BSE Sensex^*	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 13-May-2022 | *As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2021	2020	2019	2018	2017	2016	2015
Intersect ENT (XENT)	19.3	-8.0	-11.6	-13.0	167.8	-46.2	21.3
S&P Small-Cap 600	25.3	9.6	20.9	-9.7	11.7	24.7	-3.4
BSE Sensex	22.0	15.8	14.4	5.9	27.9	1.9	-5.0

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Intersect ENT (XENT)

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat... patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California. Read more

Pres, CEO & Director

Mr. Thomas A. West
Pres, CEO & Director

Mr. Thomas A. West
Headquarters

Menlo Park, CA
Website

https://www.intersectent.com

FAQs for Intersect ENT (XENT)

What is the current share price of Intersect ENT Inc (XENT) Today?

The share price of Intersect ENT Inc (XENT) is $28.24 (NASDAQ) as of 13-May-2022 09:30 EDT. Intersect ENT Inc (XENT) has given a return of 0.91% in the last 3 years.

What is the current PB & PE ratio of Intersect ENT Inc (XENT)?

Since, TTM earnings of Intersect ENT Inc (XENT) is negative, P/E ratio is not available.
The P/B ratio of Intersect ENT Inc (XENT) is 56.40 times as on 13-May-2022, a 1369 premium to its peers’ median range of 3.84 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2021	-5.65	-13.05
2020	-10.45	11.28
2019	-17.95	6.54
2018	-36.88	6.99
2017	-57.42	8.02

What is the 52 Week High and Low of Intersect ENT Inc (XENT)?

The 52-week high and low of Intersect ENT Inc (XENT) are Rs -- and Rs -- as of 29-Aug-2026.

What is the market cap of Intersect ENT Inc (XENT)?

Intersect ENT Inc (XENT) has a market capitalisation of $ 955 Mln as on 13-May-2022. As per SEBI classification, it is a Small Cap company.

Should I invest in Intersect ENT Inc (XENT)?

Before investing in Intersect ENT Inc (XENT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.